RxDoctor Payments Data

Daniel Jimenez, MD

Family Medicine · Santa Ana, CANPI 1255466801

Payments from drug & device makers

$19,571in general payments, 2019–2025

Across 667 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Pfizer$1K
  • plus $8K from 38 others

What the payments were for

  • Speaking & faculty fees$1251%
  • Food & beverage$19,32899%
  • Education$470%
  • Other$710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,571 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$59,175
Medicare patients
135
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin138$216,342
FarxigaDapagliflozin Propanediol106$145,626
RybelsusSemaglutide65$141,513
TrulicityDulaglutide89$134,320
OzempicSemaglutide74$126,528
MyrbetriqMirabegron81$97,739
EliquisApixaban68$95,576
VascepaIcosapent Ethyl104$81,408
MounjaroTirzepatide57$70,308
JanuviaSitagliptin Phosphate35$49,737
ProliaDenosumab28$47,643
XareltoRivaroxaban30$45,752
InvokanaCanagliflozin15$27,504
LinzessLinaclotide22$20,267
GemtesaVibegron14$19,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,613$268,041139 claims
Boehringer IngelheimJardiance$567$216,342138 claims
Lilly USA, LLCTrulicity, Mounjaro$1,538$204,628146 claims
AstraZenecaFarxiga$5,074$145,626106 claims
Astellas Pharma US IncMyrbetriq$384$97,73981 claims
PfizerEliquis$1,087$95,57668 claims
Johnson & JohnsonXarelto, Invokana$1,429$73,25645 claims
MerckJanuvia$298$49,73735 claims
AmgenProlia$1,164$47,64328 claims
AbbVieLinzess$447$20,26722 claims
Sumitomo Pharma America, Inc.Gemtesa$281$19,84114 claims
GSKBreo Ellipta$718$12,68015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →